Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update

Mariacristina Parravano, Eliana Costanzo, Giulia Scondotto, Gianluca Trifirò, Gianni Virgili

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in older adults. The prognosis for the neovascular type of advanced AMD improved with the introduction of biological drugs with antiangiogenic properties, beginning with off-label bevacizumab, which was first used intravitreally in 2006. These drugs target newly formed vessels that grow beneath the center of the retina, causing loss of central vision, and they can help to maintain or improve vision. Repeated intravitreal injections are needed to achieve prolonged inhibition of proangiogenic cytokines, primarily vascular endothelial growth factor (VEGF). Major regulatory agencies have approved several molecules for AMD treatment, including ranibizumab, aflibercept, and brolucizumab. The development of further drugs was mainly targeted at prolonging anti-VEGF inhibition-thus reducing the frequency of injections-and expanding the biological targets of proangiogenic cytokine inhibition. Finally, biosimilars are already being marketed in some countries, allowing the containment of costs of AMD treatment, which are growing steadily in many settings because of the need for long-term treatment. This review summarizes the properties and clinical profiles of anti-VEGF biological drugs that are approved to treat neovascular AMD as well as ongoing research on molecules that may be marketed in the near future.
Original languageEnglish
Pages (from-to)673–692
Issue number6
Early online date16 Oct 2021
Publication statusPublished - Nov 2021


Dive into the research topics of 'Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update'. Together they form a unique fingerprint.

Cite this